FDA Designates Sangamo's (SGMO) SB-318 an Orphan Drug in Treatment of Mucopolysaccharidosis Type I (MPS I)

Source Link:

http://www.prnewswire.com/news-releases/sangamo-therapeutics-receives-orphan-drug-designation-from-the-fda-for-sb-318-genome-editing-treatment-for-mps-i-300389241.html